Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2020

View Archived Issues

'Superkiller' is broad-spectrum antiviral target

CDK4/6 inhibitors affect transcriptional landscape

PTC Therapeutics initiates phase I study of PTC-518

Intermittent schedule of CH-5126766 shows activity across several RAS-RAF-driven cancers

Peptide-conjugated ReNcell-derived EVs: a new therapeutic approach for pulmonary hypertension

Phase I data presented for AMG-890 in patients with elevated plasma Lp(a)

Neuro-drug repurposed to treat MDR Gram-negative sepsis

Pionyr initiates phase I study of its immuno-oncology candidate, PY-314

Phase II/III CAPELLA study of lenacapavir meets primary endpoint

First-in-human biomarker analysis for JNJ-55920839 in SLE

University of Kansas, Fox Chase Cancer Center describe anti-CTLA-4 antibodies

Yeda Research & Development patents polypeptides comprising propeptides of human lysyl oxidase

PROTACs targeting CDK12 and/or a CDK9 synthesized at the Dana-Farber Cancer Institute

JAK inhibitor prodrugs discovered at Theravance Biopharma

Beta Pharma identifies new HCV NS5A inhibitors

Supemtek quadrivalent recombinant influenza vaccine approved in E.U.

Preliminary phase I data for the half-life extended BiTE immune therapy, AMG-757

Bioventus receives IND clearance to study PTP-001 for knee osteoarthritis

FDA clears initiation of phase I trial of anti-LILRB2/ILT4 antibody JTX-8064

Synergy seen for DA-1241 with DPP4 inhibitor for the treatment of NASH

BioVersys initiates phase I testing of BV-100 for carbapenem-resistant A. baumannii infections

Interim data from phase Ib/IIa study of VBI-2601 for chronic hepatitis B

Genoscience completes phase Ib study of GNS-561 in primary and secondary liver cancer

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...